Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma

Author： Heath Elisabeth   Burtness Barbara   Kleinberg Lawrence   Salem Ronald   Yang Stephen   Heitmiller Richard   Canto Marcia   Knisely Jonathan   Topazian Mark   Montgomery Elizabeth   Tsottles Nancy   Pithavala Yazdi   Rohmiller Bridget   Collier Mary   Forastiere Arlene  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.24, Iss.2, 2006-03, pp. : 135-140

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combined Modality Therapy of Esophageal Cancer

By Juergens Rosalyn A.   Forastiere Arlene  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 9, 2008-10 ,pp. : 851-861

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Combined Modality Therapy of Localized Gastric and Esophageal Cancers

By Das Prajnan   Fukami Norio   Ajani Jaffer A.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 4, 2006-04 ,pp. : 375-382

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomes

By Chu Quincy   Forouzesh Bahram   Syed Samira   Mita Monica   Schwartz Garry   Cooper Joshua   Curtright Janet   Rowinsky Eric  

Investigational New Drugs, Vol. 25, Iss. 4, 2007-08 ,pp. : 357-357

Springer Publishing Company

Access to resources Recommend Favorite

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

By Chu Quincy   Forouzesh Bahram   Syed Samira   Mita Monica   Schwartz Garry   Copper Joshua   Curtright Janet   Rowinsky Eric  

Investigational New Drugs, Vol. 25, Iss. 4, 2007-08 ,pp. : 359-367

Springer Publishing Company

Access to resources Recommend Favorite

Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue

By  

Current Pharmaceutical Design, Vol. 20, Iss. 42, 2014-12 ,pp. : 6697-6701

Bentham Science Publishers

Access to resources Recommend Favorite